https://pubmed.ncbi.nlm.nih.gov/33973272/
Now Atl1102 reduces a unique type of inflammation in the body of DMD patients.Also reduces fibrosis (Mediated fibrosis) known in DMD:
We know this by our excellent data generated.
No Pharma even close to helping non ambulant patients.
Anp is in the Box seat with DMD. / limb girdle.
So people don’t listen to the negative noise
Remember
DMD is our primary objective and that trial start is not very far away .
We wait $$ ($10 billion market for DMD in 2030)
Ann: PIIb DMD trial approved in Bulgaria- UK, Australia advancing, page-11
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $121.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 35714 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 37037 | 1 |
View Market Depth
| Last trade - 09.13am 17/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |
Day chart unavailable